NASDAQ · LIMNW
Liminatus Pharma, Inc. Warrants
Healthcare · Biotechnology
$0.05
Up+$0.00 (+0.00%)
Updated Oct 11, 2026, 1:09 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.19M
- P/E ratio
- -9.06
- Dividend yield
- 0.00%
- 52-week range
- $0.04 – $0.11
- Volume
- 800
- Avg. volume
- 49.98K
Price performance · LIMNW
LIMNW price history
1M range · 5 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
LIMNW closed at $0.05 after 5 trading sessions, down 17.03% for the selected period.
- Last close
- $0.05
- Period change
- -17.03%
- Period low
- $0.04
- Period high
- $0.06
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $0.0499 | $0.0499 | $0.0497 | $0.0497 | 800 |
| Oct 7, 2026 | $0.044 | $0.044 | $0.037 | $0.037 | 3.65K |
| Sep 30, 2026 | $0.0495 | $0.0555 | $0.0494 | $0.0555 | 1.21K |
| Sep 29, 2026 | $0.0445 | $0.0445 | $0.0445 | $0.0445 | 194 |
| Sep 23, 2026 | $0.0599 | $0.0599 | $0.0599 | $0.0599 | 200 |
Latest LIMNW news
The latest Smart Investors Daily articles mentioning LIMNW.
Stock researchCompany · Overview
Company
Market Activity
Research & News
LIMNW research
Overview
Company profile and research snapshot.
Company profile
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
